Sarah Davis MPhys

Sarah Davis

HEDS, ScHARR
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA

Office: 1011

Tel: (+44) (0)114 222 5209
Fax: (+44) (0)114 222 0749

E-mail: s.davis@sheffield.ac.uk

ORCiD: 0000-0002-6609-4287

Biography

I returned to ScHARR in January 2010 after spending three years working on NICE Clinical Guidelines. I started in November 2006 as Senior Health Economist at the National Collaborating Centre for Nursing and Supportive Care which developed Clinical Guidelines for NICE. When this centre was merged with three others to form the National Clinical Guideline Centre (NCGC) in April 2009, I joined the NCGC as Health Economics Lead.

Prior to this period, I was a cost-effectiveness modeller within the HEDS section at ScHARR where I worked on NICE Technology Appraisals, NICE Clinical Guidelines, Health Technology Assessments and consultancy projects for the pharmaceutical industry.

I am currently Deputy Director of the NICE Decision Support Unit (DSU). The DSU is commissioned by The National Institute for Health and Clinical Excellence (NICE) to provide a research and training resource to support the Institute's Technology Appraisal Programme.

Research interests

My research interests are cost-effectiveness modelling, technology appraisal, and clinical guideline development.

Teaching interests

My teaching interests include decision modelling in health care and supporting non-health economists to engage with health economic evidence when developing guidance for the NHS.

Professional activities

Guideline Development Group member for the following NICE Clinical Guidelines:

  • Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care (Nov 2006 to Feb 2008)
  • Management of inadvertent perioperative hypothermia in adults (Nov 2006 to Apr 2008)
  • Delirium: diagnosis, prevention and management (Jul 2008 to Jul 2010)
  • Management of transient loss of consciousness in adults (Jun 2008 to Aug 2010)

Current projects

  • Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs (08/118/01)
  • Various projects for the DSU (see link)

Extended List of Publications

Journal articles